EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Zhengye Biotechnology Holding Limited (ZYBT) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Zhengye Biotechnology Holding Limited $0.26, price $1.31, upside -80.1%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN KYG989MS1016

ZB Zhengye Biotechnology Holding Limited logo Thin data Sep 27, 2026

Zhengye Biotechnology Holding Limited

ZYBT · US

Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.2600 · Strongly overvalued (−80.1%)
!Quality 36/100
!Weak Growth (revenue 3y −23.5 %/yr)
!Loss-making · -60.0% net margin (TTM)
✓Low debt · generates free cash flow
!Trails peers (3/11)
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain
Watch Zhengye Biotechnology Holding Limited Ordinary Shares for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$14.15 $0.6460 Fair Value $0.2600 Jan 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

21‑month range $0.6460 – $14.15 · fair‑value band $0.2300 – $0.3200 · the $1.31 price screens above the $0.2600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow Zhengye Biotechnology Holding Limited Ordinary Shares in your weekly email

Every Wednesday you see whether Zhengye Biotechnology Holding Limited Ordinary Shares is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.

Show more

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs. In addition, the company exports its products to Vietnam, Pakistan, and Egypt. It serves direct-end customers, including livestock farmers and local governments; and domestic distributors and exporting distributors. The company was incorporated in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.

Stock analysis

Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) currently trades at $1.31, while our model-based Fair Value estimate is $0.2600, implying the stock looks roughly 402.0% overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $1.80 per share, and 6 of the 8 models we run sit above the $1.31 price.

Bear case: the Multiples group reads lowest at $1.07, and 2 of the 8 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.2300 (bear) to $0.3200 (bull), the price of $1.31 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Zhengye Biotechnology Holding Limited Ordinary Shares reported revenue of 116M CNY in FY2025 versus 214M CNY in FY2021, a compound −14.1%/yr. Reported net income was −69.8M CNY in FY2025.

Key figures

Market cap $61.6M · P/S ratio 0.31 · EPS (TTM) $−0.2200 · Net margin −60.0% · Return on equity −25.2% · Return on assets (EBIT) 4.3% · Operating margin −77.0% · Revenue (TTM) 116M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 84% below its 52-week high and 102% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −80%, ZYBT screens richer than that median.

Fair Value models

Bear $0.2300 Fair Value $0.2600 Bull $0.3200
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $1.54 $1.78 $2.21 79
Growth DCF $1.57 $1.80 $2.19 77
5Y Revenue Exit $1.21 $1.29 $1.39 71
All 8 models by family
DCF Models
FCF DCF $1.54 $1.78 $2.21 79
5Y Revenue Exit $1.21 $1.29 $1.39 71
10Y Revenue Exit $1.34 $1.40 $1.46 65
Dividend Discount
Gordon GGM $2.97 $3.24 $3.64 67
DDM Multi-Stage $2.97 $3.67 $4.62 65
Multiples
EV/Revenue $1.01 $1.07 $1.13 54
Asset-Based
NCAV (Graham) $2.64 $3.53 $5.27 54
Growth DCF
Growth DCF $1.57 $1.80 $2.19 77

Open the full fair value analysis →

Notify me when ZYBT reaches fair value

Put ZYBT on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 36/100

Of which business quality 36 · Market factors (momentum, volatility) 31

Profitability 4
Margins and returns on capital today
Quality Growth 0
Are margins and returns improving?
Cashflow 22
Earnings quality: real cash, not paper profit
Fin. Strength 52
Balance sheet, leverage, solvency risk
Investment 84
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 67
Price trend over the last 3–12 months (market factor)
52W Momentum 5
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 18/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−37.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−23.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
24.5% (2021) → −58.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.

ZYBT screens 402% overvalued. Compare with Merck KGaA →

Compare Zhengye Biotechnology Holding Limited Ordinary Shares with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 621 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Bottom 25%
Fair Value upside −80.1% · Bottom 25%
Profitability
Return on assets −9.5% · Bottom 25%
Net margin (TTM) −60.0% · Bottom 25%
Operating margin (TTM) −77.0% · Bottom 25%
Growth and dividend
Revenue growth −40.9% · Bottom 25%
Balance sheet
Debt / equity 0.04× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.25× · Cheapest 25%
P/S (TTM) 0.53× · Cheapest 25%
P/FCF 87.6× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)0 · sector 18
PAST (return on equity)0 · sector 26
HEALTH (low debt)98 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €135.00 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.86 $11.40 −40%
Teva Pharmaceutical Industries Limited TEVA $39.19 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $71.05 $110.50 +56%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Zhengye Biotechnology Holding Limited Ordinary Shares · Fair Value
$0.2600 −402%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Zhengye Biotechnology Holding Limited Ordinary Shares Fair Value". https://www.fairvalue-calculator.com/stock/ZYBT

Frequently asked questions

Is Zhengye Biotechnology Holding Limited (ZYBT) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.2600 versus a price of $1.31, about −80% upside (overvalued).
What is the fair value of ZYBT?
Our model-based fair value for Zhengye Biotechnology Holding Limited Ordinary Shares is $0.2600 (as of Sep 27, 2026), built from audited fundamentals. The current price: $1.31.
What is the quality score of ZYBT?
Zhengye Biotechnology Holding Limited Ordinary Shares has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhengye Biotechnology Holding Limited (ZYBT)?
Our model-based price target is the fair value of $0.2600 (as of Sep 27, 2026) from 8 valuation models. Cautious scenario $0.2300, optimistic scenario $0.3200. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhengye Biotechnology Holding Limited Ordinary Shares stock forecast for 2026?
Our models put fair value at $0.2600, about −80% upside versus a price of $1.31 (overvalued). Cautious scenario $0.2300, optimistic scenario $0.3200. The calculation is refreshed regularly with new filings.
What is the revenue of Zhengye Biotechnology Holding Limited (ZYBT)?
Zhengye Biotechnology Holding Limited Ordinary Shares reported trailing-twelve-month revenue of about 116M CNY (latest available figure, as of Sep 27, 2026).
What growth is priced into Zhengye Biotechnology Holding Limited (ZYBT)?
For today's price to be fair in a discounted-cash-flow model, Zhengye Biotechnology Holding Limited Ordinary Shares would have to grow free cash flow by more than 80 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew -14.1 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of ZYBT use?
Our models discount Zhengye Biotechnology Holding Limited Ordinary Shares at 9.7 %: a base by market capitalisation (nano), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Zhengye Biotechnology Holding Limited Ordinary Shares that is more than 80 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has Zhengye Biotechnology Holding Limited (ZYBT) delivered so far?
Over the past 4 years revenue at Zhengye Biotechnology Holding Limited Ordinary Shares grew -14.1 % a year. The price currently implies more than 80 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Zhengye Biotechnology Holding Limited (ZYBT) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Zhengye Biotechnology Holding Limited Ordinary Shares (more than 80 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Zhengye Biotechnology Holding Limited (ZYBT)?
The free-cash-flow yield on the price is 0.17 %: that much free cash flow Zhengye Biotechnology Holding Limited Ordinary Shares produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Zhengye Biotechnology Holding Limited (ZYBT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhengye Biotechnology Holding Limited Ordinary Shares it is $0.2600 per share (as of Sep 27, 2026), against a price of $1.31. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is Zhengye Biotechnology Holding Limited Ordinary Shares stock overvalued or undervalued in 2026?
As of Sep 27, 2026, ZYBT trades above its calculated fair value: price $1.31, fair value $0.2600, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ZYBT?
No. The price is what the market pays today ($1.31); the fair value is what the company's own numbers justify ($0.2600). For Zhengye Biotechnology Holding Limited Ordinary Shares the two are $1.05 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhengye Biotechnology Holding Limited Ordinary Shares worth?
The market values Zhengye Biotechnology Holding Limited Ordinary Shares at about $61.6M (market capitalisation, as of Sep 27, 2026). Per share that is $1.31; our models calculate a fair value of $0.2600 per share.
What do the bullish and bearish scenarios say about ZYBT?
Our models span a range for Zhengye Biotechnology Holding Limited Ordinary Shares: cautious scenario $0.2300, base $0.2600, optimistic $0.3200 per share (as of Sep 27, 2026, price $1.31). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Zhengye Biotechnology Holding Limited (ZYBT)?
Balance-sheet figures for Zhengye Biotechnology Holding Limited Ordinary Shares (as of Sep 27, 2026): return on equity −25.2%, debt of 0.04 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is ZYBT from its 52-week high?
Zhengye Biotechnology Holding Limited Ordinary Shares trades at $1.31, about 84% below its 52-week high of $8.01 and 102% above the low of $0.6460 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2600 is for.
Which stocks are comparable to Zhengye Biotechnology Holding Limited Ordinary Shares?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhengye Biotechnology Holding Limited Ordinary Shares stock attractive at the current price?
The data as of Sep 27, 2026: price $1.31, calculated fair value $0.2600 (−80%), Quality Score 36/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ZYBT calculated?
We run Zhengye Biotechnology Holding Limited Ordinary Shares through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2600, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Zhengye Biotechnology Holding Limited Ordinary Shares itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhengye Biotechnology Holding Limited (ZYBT)?
The closing price on Sep 25, 2026 was $1.31. Our model-based fair value is $0.2600, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhengye Biotechnology Holding Limited Ordinary Shares right now?
The price sits above even our optimistic bull case ($0.3200). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Zhengye Biotechnology Holding Limited Ordinary Shares

How large is the market capitalisation of Zhengye Biotechnology Holding Limited (ZYBT)?
The market capitalisation of Zhengye Biotechnology Holding Limited Ordinary Shares is $61.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhengye Biotechnology Holding Limited (ZYBT)?
The price-to-sales ratio of Zhengye Biotechnology Holding Limited Ordinary Shares is 0.31 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhengye Biotechnology Holding Limited (ZYBT)?
Earnings per share at Zhengye Biotechnology Holding Limited Ordinary Shares are $−0.2200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Zhengye Biotechnology Holding Limited (ZYBT)?
The net margin of Zhengye Biotechnology Holding Limited Ordinary Shares is −60.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhengye Biotechnology Holding Limited (ZYBT)?
The return on equity (ROE) of Zhengye Biotechnology Holding Limited Ordinary Shares is −25.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhengye Biotechnology Holding Limited (ZYBT)?
On an EBIT basis the return on assets of Zhengye Biotechnology Holding Limited Ordinary Shares is 4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhengye Biotechnology Holding Limited (ZYBT)?
The operating margin of Zhengye Biotechnology Holding Limited Ordinary Shares is −77.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhengye Biotechnology Holding Limited (ZYBT)?
Revenue at Zhengye Biotechnology Holding Limited Ordinary Shares is growing −40.9% versus a year earlier (3y avg −23.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zhengye Biotechnology Holding Limited (ZYBT)?
Earnings per share at Zhengye Biotechnology Holding Limited Ordinary Shares are growing −79.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Zhengye Biotechnology Holding Limited (ZYBT) carry?
The net debt of Zhengye Biotechnology Holding Limited Ordinary Shares is 24.8M CNY (fiscal year 2025, ≈ 35.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Zhengye Biotechnology Holding Limited Ordinary Shares in the live analysis

One click puts Zhengye Biotechnology Holding Limited Ordinary Shares on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.